ZYXI:NSD-Zynex Inc (USD)

COMMON STOCK | Medical Distribution |

Last Closing

USD 7.19

Change

-0.22 (-2.97)%

Market Cap

N/A

Volume

0.22M

Analyst Target

USD 27.35
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-21 )

Largest Industry Peers for Medical Distribution

Symbol Name Price(Change) Market Cap
HSIC Henry Schein Inc

-0.81 (-1.04%)

USD 9.93B
PDCO Patterson Companies Inc

+0.01 (+0.03%)

USD 2.73B
AHG Akso Health Group ADR

-0.03 (-2.26%)

USD 0.35B
EDAP EDAP TMS SA

-0.14 (-5.15%)

USD 0.11B
YI 111 Inc

+0.16 (+1.95%)

USD 0.05B
COSM Cosmos Health Inc.

-0.01 (-1.89%)

N/A
SNYR Synergy CHC Corp. Common Stock

-0.01 (-0.13%)

N/A

ETFs Containing ZYXI

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Distribution) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.24% 25% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.24% 25% F 27% F
Trailing 12 Months  
Capital Gain -44.31% 25% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.31% 25% F 20% F
Trailing 5 Years  
Capital Gain -33.31% 57% F 33% F
Dividend Return 0.93% 50% F 3% F
Total Return -32.39% 57% F 31% F
Average Annual (5 Year Horizon)  
Capital Gain -5.63% 25% F 26% F
Dividend Return -5.63% 25% F 25% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 38.62% 75% C 49% F
Risk Adjusted Return -14.58% 25% F 26% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.